Saad Z. Usmani, MD
Although the importance of achieving minimal residual disease (MRD) negativity in patients with multiple myeloma has been established, further application in practice is dependent on phase III findings from ongoing trials, explains Saad Z. Usmani, MD.
on Multiple Myeloma and Myeloproliferative Neoplasms, Usmani, who was chair of the program, discussed the clinical applications of MRD and managing patients with relapsed/refractory multiple myeloma.
OncLive: Please provide an overview of your presentation.
I spoke about MRD, the importance of depth of response in myeloma, and where that data come from. Then, I segued into some clinical data with prospective clinical trials looking at MRD negativity with different methodologies. There [are many] unanswered questions. Ultimately, MRD status should not be used to change treatment.
... to read the full story